6 GSK Annual Report 2012 Strategic review How we performed We measure our performance against a number of key indicators, and use core results for our planning and reporting purposes b, c Group turnover Free cash ow bn bn 2.0 26.4 15 8 51 Reported growth % 1 3 1 Reported growth CER % 19 14 17 Growth excluding legal settlements % 4 3 Reported growth % How we performed How we performed 28.4 4.5 27.4 Reported sales were down 1% but were at Free cash ow was 2.0 billion.
Excluding 26.4 4.1 adjusting for the disposal of our non-core OTC legal settlements, adjusted free cash ow was Consumer Healthcare brands.
performances in EMAP and other growth Why its important businesses largely offset declines in USA This measure shows the cash we generate that and Europe.
is available to return to shareholders or reinvest 2.0 Why its important in the business, as well as our effectiveness in A key objective of our strategy is to deliver converting our earnings to cash through effective sustainable, broadly-sourced sales growth.
working capital control and investment discipline.
2010 2011 2012 2010 2011 2012 a Core operating profit and margin Total operating profit and margin bn bn 8.3 7.4 4 6 3 Reported growth CER % 59 100 3 Reported growth CER % 7 5 Reported growth % 55 100 5 Reported growth % How we performed How we performed 33.4% 28.5% 28.0% Core operating profit was 8.3 billion.
Core Total operating profit was 7.4 billion.
Total 32.1% 9.5 31.5% 7.8 operating margin declined 0.6 percentage operating margin declined 0.5 percentage 7.4 8.8 8.3 points to 31.5%, of which 0.3 percentage points to 28.0%, of which 0.3 percentage points was due to the expected impact of points was due to the expected impact of the acquisition of Human Genome Sciences.
the acquisition of Human Genome Sciences.
13.3% Why its important 3.8 Our objective remains to improve operating leverage.
The margin indicates how costs are being managed as sales grow.
2010 2011 2012 2010 2011 2012 a Core earnings per share Total earnings per share 112.7 p 92.9p 3 7 Reported growth CER % 75 100 9 Reported growth CER % 8 2 Reported growth % 71 100 11 Reported growth % How we performed How we performed 104.6 125.5 Effective cost control and delivery of financial Non-core items included a tax charge of 115.5 112.7 92.9 efficiencies enabled the Group to deliver core 420 million 8.6p arising from the EPS of 112.7p centralisation of Pharmaceutical intellectual property and product inventory ownership Why its important in the UK.
Transactions completed in 2012 EPS shows the portion of our profit allocated resulted in a number of significant non-cash to each share.
It is a key indicator of our accounting entries.
However, these largely performance and the returns we are generating.
32.1 2010 2011 2012 2010 2011 2012 2-54 Strategic review 55-86 Financial review & risk 87-136 Governance & remuneration 137-223 Financial statements 224-248 Investor information GSK Annual Report 2012 7 b b Turnover in our major growth areas New Pharmaceuticals and Vaccines product performance bn bn 14.3 1.4 51 53 54 % share of total turnover 36 47 34 Reported growth CER % How we performed How we performed 14.6 2.5 14.4 14.3 We saw continued growth in emerging markets, Total sales of new products were 1.4 billion, Japan excluding vaccines and Consumer grew 34% in the year and represented 7% Healthcare excluding disposals.
Performance of Pharmaceutical and Vaccines turnover.
in Vaccines was impacted by reduced sales of 2012 was impacted by the roll-off of products 1.7 Cervarix following the HPV vaccination more than five years old.
1.4 catch-up programme in Japan in 2011.
Why its important Why its important This measure shows the delivery of sales This measure focuses on our major growth from products launched in the prior five areas: Vaccines, Consumer Healthcare, EMAP, years and creates incentives for improved Japan and dermatology.
2010 2011 2012 2010 2011 2012 b, d Cash returned to shareholders Relative total shareholder return 160 bn 6.3 140 775 13 Reported growth % 6.3 120 2.5 5.6 How we performed 2.2 During 2012, GSK returned 6.3 billion to shareholders via dividends and share 100 buybacks.
3.2 3.8 Why its important 80 3.4 We continue to focus on delivering dividend growth and returning free cash ow to shareholders through share buy-backs where 60 this offers a more attractive return than 31 12 07 31 12 08 31 12 09 31 12 10 31 12 11 31 12 12 alternative investments.
W GlaxoSmithKline Total Return GlaxoSmithKline Pharma Peers Return Index FTSE 100 Total Return Index 2010 2011 2012 a b We use a number of adjusted measures to report the performance The remuneration of our executives is linked to the marked key of our business.
These include core results, which are used by indicators.
Further information on our executive pay policy can be management for planning and reporting purposes and may not found in our Remuneration report on page 109. be directly comparable with similarly described measures used by c The calculation of free cash ow is described on page 56 and a other companies.
Core results exclude a number of items from total reconciliation is provided on page 69.
The calculation of CER is results.
A full denition of core results can be found on page 56 and described on page 56. a reconciliation between core results and total results is provided on page 62. d The constituents of the Pharma Peers Return Index are listed on page 115. Dividend BuyDividend backs BuyDividend backs
